A new level of precision
Small molecule drugs can lack precision and their actual target may not be known, making them toxic. Antibody drugs are very precise but typically lack potency. Antibody Drug Conjugates (ADCs) combine the precision of antibodies with the potency of small molecule drugs yet are hindered by two requirements, cell internalization and degradation.
Build ADCs that don’t require cell internalization nor degradation.
Centrose’s Extracellular Drug Conjugate (EDC) technology produces a new type of ADC that do not require internalization nor degradation. Using antibodies, EDCs precisely place potent drugs within angstroms of an extracellular target. This way, EDCs have reduced off-target toxic side effects and high drug potency because they don’t enter cells and they don’t degrade.
Today, most drugs for life threatening diseases like cancer are extremely toxic and prone to resistance. Older chemo drugs tend to kill all cells and advanced targeted drugs suffer from drug resistance.
In an effort to make potent therapies less toxic, Centrose created EDC Technology. EDC Technology exploits the fact that diseased cells construct unique and complex multi-protein structures on their surfaces. These structures are critical for cancer cell survival and many were first discovered at Centrose.
Centrose’s first-line therapies target these structures and kill by a process called “targeted necrosis”. Necrosis is an alternative cell death pathway that has yet to be fully understood but Centrose believes targeted necrosis may overcome drug resistance and make tumors "hot", which is an important goal when treating patients with immune checkpoint inhibitors like Yervoy and Keytruda.
As reported in our cell press publication, Centrose discovered that drug targets were interacting with cancer markers. Along with this came the idea that antibodies could be used to deliver drugs with exquisite precision using EDC Technology. The EDCs described in the publication starve the cells for food, shut down their ability to transport nutrients and induce necrosis, offering completely new mechanisms for treating cancer.
LEAD and PIPELINE
Centrose's lead candidate is EDC9 which uses a generic Rituximab to target and kill CD20 positive cancers. EDC9 will initially be tested on patients with drug resistant Non-Hodgkin's Lymphomas (NHL). Centrose’s EDC1 kills metastatic cancers that express dysadherin, a protein that allows cancer cells to separate from tumor masses and spread throughout the body. Centrose’s EDC8 targets CD38 positive cells. CD38 forms protein complexes on the surface of Acute Myeloid Leukemia (AML) cells.